Pay in 4 interest-free payments of $5.88 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
Our physicians will guide this transition with an appropriate overlap or washout protocol and a carefully calibrated starting dose for the new medication
Alport syndrome: a unified classification of genetic disorders of collagen IV 345: a position paper of the Alport Syndrome Classification Working Group
GLP-1 RAs reduce major cardiovascular events by 14% through multiple mechanisms beyond glucose control, including anti-inflammatory effects and blood pressure reduction SELECT trial proved cardiovascular benefits extend to non-diabetic patients with obesity, showing 20% MACE reduction in those without diabetes Semaglutide, liraglutide, and dulaglutide demonstrate the strongest cardiovascular protection, with proven benefits in large outcome trials These agents provide specific benefits for heart failure with preserved ejection fraction and kidney protection, reducing albuminuria by 24% Current guidelines strongly recommend GLP-1 RAs for patients with established cardiovascular disease, regardless of diabetes status or HbA1c levels The evidence positions GLP-1 receptor agonists as fundamental cardiovascular medications rather than merely diabetes drugs with heart benefits
Medication errors in community pharmacies: The need for commitment, transparency, and research
R., Ghaderabad, M
Some patients experience postural dizziness, particularly when starting therapy
